Recent advances in ICB therapy, such as targeting programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), illustrate powerful enhancement of the patient’s anti-tumor immune responses [13]. This evidence concerns the gene CD274 and neoplasm.